199 research outputs found
Recommended from our members
Relationship between diffusion capacity and small airway abnormality in COPDGene.
Impaired single breath carbon monoxide diffusing capacity (DLCO) is associated with emphysema. Small airways disease (SAD) may be a precursor lesion to emphysema, but the relationship between SAD and DLCO is undescribed. We hypothesized that in mild COPD, functional SAD (fSAD) defined by computed tomography (CT) and Parametric Response Mapping methodology would correlate with impaired DLCO. Using data from ever-smokers in the COPDGene cohort, we established that fSAD correlated significantly with lower DLCO among both non-obstructed and GOLD 1-2 subjects. The relationship between DLCO with CT-defined emphysema was present in all GOLD stages, but most prominent in severe disease. TRIAL REGISTRATION: NCT00608764. Registry: COPDGene. Registered 06 February 2008, retrospectively registered
Chronic Airways Assessment Test : Psychometric properties in patients with asthma and/or COPD
Acknowledgements The authors would like to thank the patients who participated in this study and wish to acknowledge the work of the NOVELTY Scientific Community and the NOVELTY study investigators, who are listed in full below, and Sharon MacLachlan (Evidera, London, UK), who participated in the analysis of sections of the data. Medical writing support, under the direction of the authors, was provided by Niall Tyrer, MBiolSci, CMC Connect, a division of IPG Health Medical Communications, funded by AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med 2022; 175(9):1298ā1304). Funding The NOVELTY study was funded by AstraZeneca.Peer reviewedPublisher PD
Validation of a diagnosis-agnostic symptom questionnaire for asthma and/or COPD
ACKNOWLEDGEMENTS The authors wish to acknowledge the work of the NOVELTY study investigators, who are listed in full in the supplementary material, and Sharon MacLachlan (Evidera, London, UK), who participated in the analysis of sections of the data. Medical writing support, under the direction of the authors, was provided by Lauren McNally, MSci, CMC Connect, McCann Health Medical Communications, and was funded by AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015; 163: 461ā464). Support statement: The NOVELTY study is funded by AstraZenecaPeer reviewedPublisher PD
Validation of the Chronic Airways Assessment Test in the NOVELTY Study
Peer reviewedPostprin
Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene.
BackgroundPreserved Ratio Impaired Spirometry (PRISm), defined as a reduced FEV1 in the setting of a preserved FEV1/FVC ratio, is highly prevalent and is associated with increased respiratory symptoms, systemic inflammation, and mortality. Studies investigating quantitative chest tomographic features, genetic associations, and subtypes in PRISm subjects have not been reported.MethodsData from current and former smokers enrolled in COPDGene (nā=ā10,192), an observational, cross-sectional study which recruited subjects aged 45-80 with ā„10 pack years of smoking, were analyzed. To identify epidemiological and radiographic predictors of PRISm, we performed univariate and multivariate analyses comparing PRISm subjects both to control subjects with normal spirometry and to subjects with COPD. To investigate common genetic predictors of PRISm, we performed a genome-wide association study (GWAS). To explore potential subgroups within PRISm, we performed unsupervised k-means clustering.ResultsThe prevalence of PRISm in COPDGene is 12.3%. Increased dyspnea, reduced 6-minute walk distance, increased percent emphysema and decreased total lung capacity, as well as increased segmental bronchial wall area percentage were significant predictors (p-value <0.05) of PRISm status when compared to control subjects in multivariate models. Although no common genetic variants were identified on GWAS testing, a significant association with Klinefelter's syndrome (47XXY) was observed (p-valueā<ā0.001). Subgroups identified through k-means clustering include a putative "COPD-subtype", "Restrictive-subtype", and a highly symptomatic "Metabolic-subtype".ConclusionsPRISm subjects are clinically and genetically heterogeneous. Future investigations into the pathophysiological mechanisms behind and potential treatment options for subgroups within PRISm are warranted.Trial registrationClinicaltrials.gov Identifier: NCT000608764
Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease
Background The value of quantitative CT (QCT) to
identify chronic obstructive pulmonary disease (COPD)
phenotypes is increasingly appreciated. The authors
hypothesised that QCT-defined emphysema and airway
abnormalities relate to St Georgeās Respiratory
Questionnaire (SGRQ) and Body-Mass Index, Airflow
Obstruction, Dyspnea and Exercise Capacity Index
(BODE).
Methods 1200 COPDGene subjects meeting Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
criteria for COPD with QCT analysis were included. Total
lung emphysema was measured using the density mask
technique with a 950 Hounsfield unit threshold. An
automated programme measured mean wall thickness
(WT), wall area percentage (WA%) and 10 mm lumenal
perimeter (pi10) in six segmental bronchi. Separate
multivariate analyses examined the relative influence of
airway measures and emphysema on SGRQ and BODE.
Results In separate models predicting SGRQ score, a 1
unit SD increase in each airway measure predicted higher
SGRQ scores (for WT, 1.90 points higher, p=0.002; for
WA%, 1.52 points higher, p=0.02; for pi10, 2.83 points
higher p<0.001). The comparable increase in SGRQ for
a 1 unit SD increase in emphysema percentage in these
models was relatively weaker, significant only in the pi10
model (for emphysema percentage, 1.45 points higher,
p=0.01). In separate models predicting BODE, a 1 unit
SD increase in each airway measure predicted higher
BODE scores (for WT, 1.07-fold increase, p<0.001; for
WA%, 1.20-fold increase, p<0.001; for pi10, 1.16-fold
increase, p<0.001). In these models, emphysema more
strongly influenced BODE (range 1.24-1.26-fold increase,
p<0.001).
Conclusion Emphysema and airway disease both relate
to clinically important parameters. The relative influence
of airway disease is greater for SGRQ; the relative
influence of emphysema is greater for BODE.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91946/1/2012 Thorax Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease.pd
The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials.
BackgroundWhen discontinuation in COPD randomized controlled trials (RCTs) is unevenly distributed between treatments (differential dropout), the capacity to demonstrate treatment effects may be reduced. We investigated the impact of the time of differential dropout on exacerbation outcomes in RCTs, in relation to study duration and COPD severity.MethodsA post hoc analysis of 2,345 patients from three RCTs of 6- and 12-month duration was performed to compare budesonide/formoterol and formoterol in moderate, severe, and very severe COPD. Outcomes were exacerbation rate, time-to-first exacerbation, or discontinuation; patients were stratified by disease severity. Outcomes were studied by censoring data monthly from 1 to 12 months.ResultsIn patients treated with budesonide/formoterol, annualized exacerbation rates (AERs) were comparable for each study duration (rate ratio [RR] =0.6). With formoterol, the AER decreased with study duration (RR =1.20 at 1 month to RR =0.86 at 12 months). There was a treatment-related difference in exacerbation rates of 45%-48% for shorter study durations (ā¤4 months) and 27% for 12-month duration. This treatment-related difference in exacerbation rates was comparable for the three disease severities in studies ā¤4 months (range: 39%-51%), but this difference decreased with longer study durations, especially in more severe groups (22% and 29% at 12 months). There were fewer discontinuations with budesonide/formoterol; the treatment-related difference in time-to-first discontinuation decreased by study duration (35%, 30%, 26%, and 22% at 3, 6, 9, and 12 months, respectively). Numbers of differential dropouts increased with increasing disease severity, being greatest during second, third, and fourth months.ConclusionsCOPD severity and study duration impact exacerbation as an outcome in double-blind RCTs. This effect is most obvious in patients with severe/very severe COPD and in studies that are longer than 4 months. Early differential dropout particularly impacts study outcome, producing a "healthy survivor effect," which reduces estimations of treatment impact on exacerbations
Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
Background and objectiveLarge clinical trials have confirmed the long-term efficacy of inhaled corticosteroid/long-acting Ī²2-agonist combinations in patients with chronic obstructive pulmonary disease (COPD). It was hypothesized that significant treatment effects would already be present within 3 months after the initiation of treatment across a range of clinical outcomes, irrespective of COPD severity.MethodsPost hoc analysis of 3-month post-randomization outcomes, including exacerbation rates, dropouts, symptoms, reliever use, and lung function, from three studies with similar inclusion criteria of moderate-to-very-severe COPD. Patients (n=1,571) were treated with budesonide/formoterol (B/F) 320/9 Ī¼g or placebo, twice daily; in one study, tiotropium 18 Ī¼g once daily was also given.ResultsOver the first 3 months of treatment, fewer patients randomized to B/F experienced exacerbations versus the placebo group (111 and 196 patients with ā„1 exacerbation, respectively). This was true in each COPD severity group. Compared with placebo, B/F treatment led to significantly lower 3-month exacerbation rates in the moderate and severe COPD severity groups (46% and 57% reduction, respectively), with a nonsignificant reduction (29%) in very severe COPD. Fewer dropouts occurred among patients treated with B/F versus placebo, this effect being greater with increasing COPD severity. B/F was associated with improved forced expiratory volume in 1 s, morning peak expiratory flow rate, total reliever use, and total symptom score versus placebo.ConclusionTreatment with B/F decreased exacerbations in patients with moderate-to-very-severe COPD within 3 months of commencing treatment. This effect was paralleled by improved lung function, less reliever medication use, and fewer symptoms, irrespective of disease severity
- ā¦